facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

DOVATO- dolutegravir sodium and lamivudine tablet, film coated


  1. Patient Information
  2. If You Have Both Human Immunodeficiency Virus-1 (hiv-1) And Hepatitis B Virus (hbv) Infection, Dovato Can Cause Serious Side Effects, Including:
  3. Dovato Is A Prescription Medicine That Is Used Without Other Antiretroviral Medicines To Treat Hiv-1 Infection In Adults:
  4. Before You Take Dovato, Tell Your Healthcare Provider About All Of Your Medical Conditions, Including If You:
  5. How Should I Take Dovato?
  6. If You Need To Take Iron Or Calcium Supplements, Including Multivitamins That Contain Iron Or Calcium, By Mouth During Treatment With Dovato:
  7. Allergic Reactions. Call Your Healthcare Provider Right Away If You Develop A Rash With Dovato. Stop Taking Dovato And Get Medical Help Right Away If You Develop A Rash With Any Of The Following Signs Or Symptoms:
  8. Tell Your Healthcare Provider Right Away If You Get Any Of The Following Signs Or Symptoms Of Liver Problems:
  9. Tell Your Healthcare Provider Right Away If You Get Any Of The Following Symptoms That Could Be Signs Of Lactic Acidosis:
  10. The Most Common Side Effects Of Dovato Include:
  11. How Should I Store Dovato?
  12. Active Ingredients:
  13. Inactive Ingredients:
  14. The Tablet Film-coating Contains:
  15. Manufactured For:
  16. Note To Pharmacist:
  17. Mfd For:
  18. Revised: 4/2019document Id:

Patient Information 

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Emergence of Lamivudine-Resistant HBV in Hepatitis B Co-infection

Advise all patients with HIV-1 to be tested for the presence of HBV prior to or when initiating DOVATO. Advise patients co-infected with HIV-1 and HBV that emergence of HBV variants associated with resistance to lamivudine has been reported in HIV 1 infected subjects who have received lamivudine containing antiretroviral regimens. Advise patients co-infected with HIV-1 and HBV who are being treated with DOVATO, to discuss with their healthcare provider if additional treatment should be considered for appropriate treatment of chronic HBV[

If You Have Both Human Immunodeficiency Virus-1 (hiv-1) And Hepatitis B Virus (hbv) Infection, Dovato Can Cause Serious Side Effects, Including: 

Resistant HBV infection.Your healthcare provider will test you for HBV infection before you start treatment with DOVATO. If you have HIV-1 and hepatitis B, the hepatitis B virus can change (mutate) during your treatment with DOVATO and become harder to treat (resistant). It is not known if DOVATO is safe and effective in people who have HIV-1 and HBV infection.
Worsening of HBV infection.If you have HIV-1 and HBV infection, your HBV may get worse (flare-up) if you stop taking DOVATO. A flare-up is when your HBV infection suddenly returns in a worse way than before. Worsening liver disease can be serious and may lead to death.
Do not run out of DOVATO. Refill your prescription or talk to your healthcare provider before your DOVATO is all gone.
Do not stop DOVATO without first talking to your healthcare provider.If you stop taking DOVATO, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver.

Dovato Is A Prescription Medicine That Is Used Without Other Antiretroviral Medicines To Treat Hiv-1 Infection In Adults: 

who have not received antiretroviral medicines in the past,and
without known resistance to the medicines dolutegravir or lamivudine.

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

It is not known if DOVATO is safe and effective in children.

Do not take DOVATOif you:

have ever had an allergic reaction to a medicine that contains dolutegravir or lamivudine.
take dofetilide.

Before You Take Dovato, Tell Your Healthcare Provider About All Of Your Medical Conditions, Including If You: 

have or have had liver problems, including hepatitis B or C infection.
have kidney problems.
are pregnant or plan to become pregnant. One of the medicines in DOVATO (dolutegravir) may harm your unborn baby.
You should not take DOVATO if you are planning to become pregnant or during the first 12 weeks of pregnancy.Your healthcare provider may prescribe a different medicine if you are planning to become pregnant or become pregnant during treatment with DOVATO.
If you can become pregnant, your healthcare provider will perform a pregnancy test before you start treatment with DOVATO.
If you can become pregnant, you should consistently use effective birth control (contraception) during treatment with DOVATO.
Tell your healthcare provider right away if you are planning to become pregnant, you become pregnant, or think you may be pregnant during treatment with DOVATO.
Pregnancy Registry. There is a pregnancy registry for people who take antiretroviral medicines, including DOVATO, during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.
are breastfeeding or plan to breastfeed.Do not breastfeed if you take DOVATO.
You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.
One of the medicines in DOVATO (lamivudine) passes into your breast milk.
Talk with your healthcare provider about the best way to feed your baby.

Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Some medicines interact with DOVATO. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

You can ask your healthcare provider or pharmacist for a list of medicines that interact with DOVATO.
Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take DOVATO with other medicines.

How Should I Take Dovato? 

Take DOVATO 1 time a day exactly as your healthcare provider tells you.
Take DOVATO with or without food.
Do not change your dose or stop taking DOVATO without talking with your healthcare provider.
If you take antacids, laxatives, or other medicines that contain aluminum, magnesium, or buffered medicines, DOVATO should be taken at least 2 hours before or 6 hours after you take these medicines.

If You Need To Take Iron Or Calcium Supplements, Including Multivitamins That Contain Iron Or Calcium, By Mouth During Treatment With Dovato: 

You may take these supplements at the same time that you take DOVATO with food.
If you do not take these supplements with DOVATO and food, take DOVATO at least 2 hours before or 6 hours after you take these supplements.
Do not miss a dose of DOVATO. If you miss a dose of DOVATO, take it as soon as you remember. Do not take 2 doses at the same time or take more than your prescribed dose.
Stay under the care of a healthcare provider during treatment with DOVATO.
Do not run out of DOVATO. The virus in your blood may increase and the virus may become harder to treat. When your supply starts to run low, get more from your healthcare provider or pharmacy.
If you take too much DOVATO, call your healthcare provider or go to the nearest hospital emergency room right away.

Allergic Reactions. Call Your Healthcare Provider Right Away If You Develop A Rash With Dovato. Stop Taking Dovato And Get Medical Help Right Away If You Develop A Rash With Any Of The Following Signs Or Symptoms: 

fever
generally ill feeling
tiredness
muscle or joint aches
blisters or sores in mouth
blisters or peeling of the skin
redness or swelling of the eyes
swelling of the mouth, face, lips, or tongue
problems breathing
Liver problems.People with a history of hepatitis B or C virus may have an increased risk of developing new or worsening changes in certain liver tests during treatment with DOVATO. Liver problems, including liver failure, have also happened in people without a history of liver disease or other risk factors. Your healthcare provider may do blood tests to check your liver.

Tell Your Healthcare Provider Right Away If You Get Any Of The Following Signs Or Symptoms Of Liver Problems: 

your skin or the white part of your eyes turns yellow (jaundice)
dark or tea-colored urine
light-colored stools (bowel movements)
nausea or vomiting
loss of appetite
pain, aching, or tenderness on the right side of your stomach area
Too much lactic acid in your blood (lactic acidosis).Lactic acidosis is a serious medical emergency that can lead to death.

Tell Your Healthcare Provider Right Away If You Get Any Of The Following Symptoms That Could Be Signs Of Lactic Acidosis: 

feel very weak or tired
unusual (not normal) muscle pain
trouble breathing
stomach pain with nausea and vomiting
feel cold, especially in your arms and legs
feel dizzy or light-headed
have a fast or irregular heartbeat
Lactic acidosis can also lead to severe liver problems,which can lead to death. Your liver may become large (hepatomegaly) and you may develop fat in your liver (steatosis).Tell your healthcare provider right away if you get any of the signs or symptoms of liver problems which are listed above under Liver problems . You may be more likely to get lactic acidosis or severe liver problems if you are female or very overweight (obese).
Changes in your immune system (Immune Reconstitution Syndrome)can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after you start taking DOVATO.

The Most Common Side Effects Of Dovato Include: 

headache
diarrhea
nausea
trouble sleeping
tiredness

These are not all the possible side effects of DOVATO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1 800 FDA 1088.

How Should I Store Dovato? 

Store DOVATO below 86 F (30 C).
DOVATO comes in a child-resistant package.

Keep DOVATO and all medicines out of the reach of children.

General information about the safe and effective use of DOVATO.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use DOVATO for a condition for which it was not prescribed. Do not give DOVATO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about DOVATO that is written for health professionals.

Active Ingredients: 

dolutegravir and lamivudine.

Inactive Ingredients: 

magnesium stearate, mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, sodium stearyl fumarate.

The Tablet Film-coating Contains: 

hypromellose, polyethylene glycol, titanium dioxide.

Manufactured For: 

ViiV Healthcare

Research Triangle Park, NC 27709

by:

GlaxoSmithKline

Research Triangle Park, NC 27709

Trademark is owned by or licensed to the ViiV Healthcare group of companies.

2019 ViiV Healthcare group of companies or its licensor.

DVT:1PIL

For more information go to www.DOVATO.com or call 1-877-844-8872.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Issued: 04/2019

Principal Display Panel

NDC 49702-246-13

Dovato

(dolutegravir and lamivudine)

Tablets

50 mg/300 mg

Rx Only

Note To Pharmacist: 

Do not cover ALERT box with pharmacy label.

ALERT: Find out about medicines that should NOT be taken with DOVATO.

30tablets

Each tablet contains 50 mg of dolutegravir (equivalent to 52.6 mg of dolutegravir sodium) and 300 mg of lamivudine.

This package is child-resistant.Keep out of reach of children.

Store below 30 C (86 F).

See prescribing information for dosage information.

Do not accept if membrane seal under cap is missing or broken.

Mfd For: 

ViiV Healthcare

RTP, NC 27709

by:GlaxoSmithKline, RTP, NC 27709

Trademarks owned or licensed by ViiV Healthcare.

2019 ViiV Healthcare or licensor.

www.dovato.com

Rev. 3/19

62000000031103

Dovato 30 count label
DOVATO
dolutegravir sodium and lamivudine tablet, film coated
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:49702-246
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DOLUTEGRAVIR SODIUM(UNII: 1Q1V9V5WYQ) (DOLUTEGRAVIR - UNII:DKO1W9H7M1)DOLUTEGRAVIR50 mg
LAMIVUDINE(UNII: 2T8Q726O95) (LAMIVUDINE - UNII:2T8Q726O95)LAMIVUDINE300 mg
Inactive Ingredients
Ingredient NameStrength
MAGNESIUM STEARATE(UNII: 70097M6I30)
MANNITOL(UNII: 3OWL53L36A)
MICROCRYSTALLINE CELLULOSE(UNII: OP1R32D61U)
POVIDONE K30(UNII: U725QWY32X)
SODIUM STARCH GLYCOLATE TYPE A CORN(UNII: AG9B65PV6B)
SODIUM STEARYL FUMARATE(UNII: 7CV7WJK4UI)
HYPROMELLOSE, UNSPECIFIED(UNII: 3NXW29V3WO)
POLYETHYLENE GLYCOL, UNSPECIFIED(UNII: 3WJQ0SDW1A)
TITANIUM DIOXIDE(UNII: 15FIX9V2JP)
Product Characteristics
ColorWHITEScoreno score
ShapeOVALSize19mm
FlavorImprint CodeSV;137
Contains
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:49702-246-1330 in 1 BOTTLE; Type 0: Not a Combination Product04/08/2019
2NDC:49702-246-6114 in 1 BOTTLE; Type 0: Not a Combination Product08/06/2019
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA21199404/08/2019
Labeler -ViiV Healthcare Company (027295585)

Revised: 4/2019document Id: 

b37964c0-f2c4-4cd9-889c-9d9b8cf59574Set id: 68e45422-43ed-4cfb-9356-fae88d14a53aVersion: 2Effective Time: 20190408ViiV Healthcare Company



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com